Neuroimaging – News and Features

People with a certain heart valve abnormality are at increased risk of severe heart rhythm disorders, even after successful valve surgery.

A new USC study reveals how gut-derived metabolites influence brain activity and autism-related behaviors. The research supports a gut-brain-behavior connection in ASD, suggesting that metabolites impact brain regions associated with emotion.

Researchers from Queen Mary University of London have developed an AI tool that creates synthetic yet medically accurate models of fibrotic heart tissue (heart scarring), aiding treatment planning for atrial fibrillation patients.

Researchers have developed a new AI tool, VisionMD, that can help doctors to more accurately monitor subtle motor changes, improving treatment for patients with Parkinson's disease and other movement disorders.

According to a new modeling study, the high number of CT (computed tomography) scans carried out in the United States in 2023 could cause 5 percent of all cancers in the country, equal to the number of cancers caused by alcohol.

Researchers identified a neural circuit defect in ASD that impairs the ability to redirect attention, crucial for social learning. The study suggests that interventions targeting this circuit could help improve attention-switching in ASD children.

A UCLA-led study reveals that children with chromosome 22q11.2 deletion syndrome show brain hyperconnectivity before puberty and under-connectivity after. This shift, linked to synapse loss, may drive autism and schizophrenia risk.

A study identifies key brain activity patterns involved in urinary incontinence in stroke survivors. Using fMRI, the research shows how strokes disrupt brain regions critical for bladder control, offering new insights into potential therapies.

A recent study reveals that individuals with cannabis use disorder exhibit elevated dopamine levels in brain regions tied to psychosis. Using brain imaging, researchers showed that long-term cannabis use can disrupt normal brain processes.

A clinical trial of tolebrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor, demonstrated a 31% delay in the onset of six-month confirmed disability progression in patients with non-relapsing secondary progressive multiple sclerosis.